446 related articles for article (PubMed ID: 23239986)
21. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
[TBL] [Abstract][Full Text] [Related]
22. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
[TBL] [Abstract][Full Text] [Related]
23. MutPred Splice: machine learning-based prediction of exonic variants that disrupt splicing.
Mort M; Sterne-Weiler T; Li B; Ball EV; Cooper DN; Radivojac P; Sanford JR; Mooney SD
Genome Biol; 2014 Jan; 15(1):R19. PubMed ID: 24451234
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
Tesoriero AA; Wong EM; Jenkins MA; Hopper JL; Brown MA; Chenevix-Trench G; Spurdle AB; Southey MC;
Hum Mutat; 2005 Nov; 26(5):495. PubMed ID: 16211554
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.
Mucaki EJ; Ainsworth P; Rogan PK
Hum Mutat; 2011 Jul; 32(7):735-42. PubMed ID: 21523855
[TBL] [Abstract][Full Text] [Related]
26. Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?
Moles-Fernández A; Duran-Lozano L; Montalban G; Bonache S; López-Perolio I; Menéndez M; Santamariña M; Behar R; Blanco A; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Capellá G; Pineda M; Vega A; Lázaro C; de la Hoya M; Diez O; Gutiérrez-Enríquez S
Front Genet; 2018; 9():366. PubMed ID: 30233647
[No Abstract] [Full Text] [Related]
27. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene.
Aretz S; Uhlhaas S; Sun Y; Pagenstecher C; Mangold E; Caspari R; Möslein G; Schulmann K; Propping P; Friedl W
Hum Mutat; 2004 Nov; 24(5):370-80. PubMed ID: 15459959
[TBL] [Abstract][Full Text] [Related]
28. Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort.
Leman R; Gaildrat P; Le Gac G; Ka C; Fichou Y; Audrezet MP; Caux-Moncoutier V; Caputo SM; Boutry-Kryza N; Léone M; Mazoyer S; Bonnet-Dorion F; Sevenet N; Guillaud-Bataille M; Rouleau E; Bressac-de Paillerets B; Wappenschmidt B; Rossing M; Muller D; Bourdon V; Revillon F; Parsons MT; Rousselin A; Davy G; Castelain G; Castéra L; Sokolowska J; Coulet F; Delnatte C; Férec C; Spurdle AB; Martins A; Krieger S; Houdayer C
Nucleic Acids Res; 2018 Sep; 46(15):7913-7923. PubMed ID: 29750258
[TBL] [Abstract][Full Text] [Related]
29. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.
Pagenstecher C; Wehner M; Friedl W; Rahner N; Aretz S; Friedrichs N; Sengteller M; Henn W; Buettner R; Propping P; Mangold E
Hum Genet; 2006 Mar; 119(1-2):9-22. PubMed ID: 16341550
[TBL] [Abstract][Full Text] [Related]
30. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
[TBL] [Abstract][Full Text] [Related]
31. Computational analysis of splicing errors and mutations in human transcripts.
Kurmangaliyev YZ; Gelfand MS
BMC Genomics; 2008 Jan; 9():13. PubMed ID: 18194514
[TBL] [Abstract][Full Text] [Related]
32. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Beristain E; Martínez-Bouzas C; Guerra I; Viguera N; Moreno J; Ibañez E; Díez J; Rodríguez F; Mallabiabarrena G; Luján S; Gorostiaga J; De Pablo JL; Mendizabal JL; Tejada MI
Breast Cancer Res Treat; 2007 Dec; 106(2):255-62. PubMed ID: 17262179
[TBL] [Abstract][Full Text] [Related]
33. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.
Vaca-Paniagua F; Alvarez-Gomez RM; Fragoso-Ontiveros V; Vidal-Millan S; Herrera LA; Cantú D; Bargallo-Rocha E; Mohar A; López-Camarillo C; Pérez-Plasencia C
PLoS One; 2012; 7(5):e37432. PubMed ID: 22655046
[TBL] [Abstract][Full Text] [Related]
34. Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants.
Sanoguera-Miralles L; Valenzuela-Palomo A; Bueno-Martínez E; Esteban-Sánchez A; Lorca V; Llinares-Burguet I; García-Álvarez A; Pérez-Segura P; Infante M; Easton DF; Devilee P; Vreeswijk MPG; de la Hoya M; Velasco-Sampedro EA
Clin Chem; 2024 Jan; 70(1):319-338. PubMed ID: 37725924
[TBL] [Abstract][Full Text] [Related]
35. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
36. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L
Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930
[TBL] [Abstract][Full Text] [Related]
37. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
38. Functional analysis of a large set of BRCA2 exon 7 variants highlights the predictive value of hexamer scores in detecting alterations of exonic splicing regulatory elements.
Di Giacomo D; Gaildrat P; Abuli A; Abdat J; Frébourg T; Tosi M; Martins A
Hum Mutat; 2013 Nov; 34(11):1547-57. PubMed ID: 23983145
[TBL] [Abstract][Full Text] [Related]
39. BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer.
Hadjisavvas A; Charalambous E; Adamou A; Christodoulou CG; Kyriacou K
Hum Mutat; 2003 Feb; 21(2):171. PubMed ID: 12552570
[TBL] [Abstract][Full Text] [Related]
40. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
